Sign In
Section Navigation
Common TitleTMC125-C223
Official Title A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of Etravirine (TMC125) in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations
Phase Phase IIB
ClinicalTrials.gov NCT00081978
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
  • Cohen CJ, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 2009;23:423-6.
    [PubMed Abstract]
  • TMC125-C223 Writing Group, Nadler JP, Berger DS, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007;21:F1-10.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.